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Neprilysin is a Mediator of
Alternative Renin-AngiotensinSystem Activation in the Murine
and Human Kidney
Oliver Domenig1,*, Arndt Manzel2,*, Nadja Grobe3, Eva Königshausen4,
Christopher C. Kaltenecker1, Johannes J. Kovarik1, Johannes Stegbauer4, Susan B. Gurley5,
Dunja van Oyen6, Marlies Antlanger1, Michael Bader7, Daisy Motta-Santos8,
Robson A. Santos9, Khalid M. Elased3, Marcus D. Säemann1, Ralf A. Linker2 & Marko Poglitsch6
Cardiovascular and renal pathologies are frequently associated with an activated renin-angiotensinsystem (RAS) and increased levels of its main effector and vasoconstrictor hormone angiotensin II
(Ang II). Angiotensin-converting-enzyme-2 (ACE2) has been described as a crucial enzymatic player in
shifting the RAS towards its so-called alternative vasodilative and reno-protective axis by enzymatically
converting Ang II to angiotensin-(1-7) (Ang-(1-7)). Yet, the relative contribution of ACE2 to Ang-(1-7)
formation in vivo has not been elucidated. Mass spectrometry based quantification of angiotensin
metabolites in the kidney and plasma of ACE2 KO mice surprisingly revealed an increase in Ang-(1-7),
suggesting additional pathways to be responsible for alternative RAS activation in vivo. Following
assessment of angiotensin metabolism in kidney homogenates, we identified neprilysin (NEP) to
be a major source of renal Ang-(1-7) in mice and humans. These findings were supported by MALDI
imaging, showing NEP mediated Ang-(1-7) formation in whole kidney cryo-sections in mice. Finally,
pharmacologic inhibition of NEP resulted in strongly decreased Ang-(1-7) levels in murine kidneys. This
unexpected new role of NEP may have implications for the combination therapy with NEP-inhibitors
and angiotensin-receptor-blockade, which has been shown being a promising therapeutic approach for
heart failure therapy.
The prevalence of chronic kidney disease (CKD) is increasing world-wide1 and constitutes a major health and
economic burden of modern societies2. Over-activation of the classical RAS-axis composed of the vasoconstrictor
Ang II and its receptor (angiotensin type 1 receptor; AT1R) represents a key pathogenic factor in the etiology
of CKD3,4. Thus, the RAS constitutes an attractive target complex for the pharmacological treatment of CKD5,6.
Recently, a novel branch of the RAS, termed alternative RAS-axis, has been described. Its constituents, Ang(1-7) and the cognate receptor MAS, functionally counterbalance biological effects of the classical RAS-axis7,8.
Moreover, accumulating evidence supports a cardio- and reno-protective role of this alternative RAS-axis7,9,10.
The protective hormone Ang-(1-7) is generated by various enzymes with ACE2 being its major producer11–13 by
converting Ang II to Ang-(1-7), therefore potently shifting the balance between the classical and the alternative
RAS. ACE2 deficiency results in hypertension and exaggerated renal and cardiovascular diseases10,14,15. Besides
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ACE2, other enzymes such as prolyl-carboxy-peptidase (PCP)16, prolyl-endo-peptidase (PEP)17 and Neprilysin
(NEP, neutral endopeptidase)18 have been described, that are biochemically capable of producing Ang-(1-7) from
Ang II and Ang I, respectively. Importantly, their actual contribution to renal Ang-(1-7) has not been elucidated,
yet.
Since the combined pharmacologic blockade of NEP and AT1-receptor with LCZ696 showed significantly
reduced overall mortality in the heart failure trial PARADIGM-HF19, we were especially interested in the involvement of NEP in renal alternative RAS activation. The underlying mechanism of LCZ696 was attributed to the stabilization of vasoactive peptides including bradykinin and natriuretic peptides via NEP blockade20. Importantly,
the PARAMOUNT trial21 also observed an increase in urinary albumin secretion in LCZ696 treated patients raising questions about the involvement of NEP in kidney physiology and suggesting the presence of tissue specific
physiologically relevant actions of LCZ696. We speculated that NEP inhibition might affect the local RAS in the
kidney at the level of the alternative pathway, possibly providing a molecular explanation for clinical observations
described above. Since CKD has been shown to be the most common co-morbidity in chronic heart failure22,
proving this hypothesis is of major clinical importance and might affect future therapeutic strategies in the treatment of heart failure.
The investigation of the tissue localized RAS is technically challenging, which is reflected by the heterogeneity
of reported tissue angiotensin concentrations. The fluctuation of Ang II in plasma ranges over 3 orders of magnitude23–25 while actual physiological levels range between 10 to 100 pg/ml26–28. To overcome some of the previous
technical limitations, we used chemically identical isotope-labelled peptides as internal standards29,30 for the multiplex liquid chromatography-tandem mass spectrometry (LC-MS/MS) based quantification of 10 angiotensin
metabolites in plasma and tissue27,31. This highly specific method allowed us to investigate RAS metabolic pathways and circulating as well as equilibrium angiotensin concentrations at a new level of detail. We characterized
RAS enzymes and peptide metabolites in wild-type and ACE2 knockout (ACE2 KO) mice, being a well described
model for studying the alternative RAS14,15. In order to assess potential clinical/therapeutic implications of our
findings in murine tissue, we extended our angiotensin metabolic analyses to biopsies of living human kidney
transplant donors.

Results

Increased RAS activity and elevated Ang-(1-7) levels in the ACE2 KO kidney.

Kidney angiotensin
concentrations of ACE2 knockout (ACE2 KO) and wild-type littermate control mice were quantified by LC-MS/MS.
A highly significant increase (p < 0.001) of angiotensin I (Ang I) was observed in ACE2 KO mice, which was
accompanied by elevated concentrations of its downstream metabolites including Ang II (p = 0.027) and Ang-(1-7)
(p = 0.023) (Fig. 1a). The ratios Ang-(1-7)/Ang I and Ang-(1-7)/Ang II were not significantly altered (Table 1).
The quantification of circulating (Supplementary Fig. 1a) and equilibrium (Supplementary Fig. 1b) angiotensin
levels in murine plasma revealed increases for Ang I, Ang II, Ang-(2-8), Ang-(3-8) and Ang-(1-5) in ACE2 KO
animals, pointing to the enhancement of the RAS at the level of plasma renin activity.
The abundance of angiotensins in immediately stabilized plasma was lower than in kidney, which is in line
with previously published reports32. Equilibrium angiotensin levels in plasma were generally higher showing a
strong correlation with circulating angiotensin levels. Comparison of equilibrium and circulating angiotensin
levels revealed a significant increase of the Ang II/Ang I ratio.
As angiotensin quantification suggested an increase in plasma renin activity (PRA), we determined the concentration of AGT and plasma-renin-activity (PRA) by LC-MS/MS based Ang I formation assays. Plasma AGT
was not altered in ACE2 KO mice (Supplementary Fig. 1c), while PRA was strongly elevated as compared to
wild-type controls (31.9 [(ng/ml)/h] versus 14.5 [(ng/ml)/h], n = pool of 3 plasma samples). We further analysed
the number of renin transcripts in the kidney by RT-PCR and determined the activity of renin in kidney homogenates, showing that neither renin expression (Fig. 1b) nor renin activity (Fig. 1c), were altered in ACE2 KO mice.
We concluded that the increased plasma renin activity was likely due to posttranscriptional or posttranslational
mechanisms such as altered secretion, since renal renin mRNA abundance as well as renin activity in kidney were
unchanged in ACE2 KO mice.

In murine kidneys, Ang II is primarily converted to Ang-(1-7) via PCP, but not ACE2.

We used
pharmacological inhibition in order to dissect the relative contribution of different Ang II metabolizing kidney proteases to Ang-(1-7) formation. Therefore, we spiked murine kidney homogenates with Ang II and
analysed its conversion to Ang-(1-7) in the presence and absence of the ACE2 inhibitor MLN-476033 and
N-benzyloxycarbonyl-prolyl-prolinal (ZPP), the dual PCP and PEP inhibitor17,18 (Fig. 2a). As expected, the renal
Ang-(1-7) formation from Ang II in wild-type was significantly higher compared to ACE2 KO (p =  0.007). MLN4760 had no effect on Ang-(1-7) formation in the ACE2 KO kidney. However, it reduced Ang-(1-7) formation in
wild-type mice to the level of ACE2 KOs. The additional presence of ZPP abolished Ang-(1-7) formation completely, assigning Ang-(1-7) formation primarily to PCP.
To better approximate the renal compartmentalization in vivo, we investigated if enzymatic distribution differs
between cortex and medulla of murine kidneys (Supplementary Fig. 2). ACE2 mediated generation of Ang-(1-7)
was higher in the cortex, whereas the relative contribution of ACE2 was still much lower compared to PCP, confirming a similar trend as observed in whole kidney homogenates (Fig. 2a).
The mRNA expression of all metabolically investigated enzymes was additionally determined in cortex and
medulla of the kidney (Supplementary Fig. 3a). The expression of the Ang II degrading enzymes ACE2 and PCP
were significantly higher in the cortex in both wild-type and ACE2 KO, supporting our previous observations
in Ang II metabolic analysis (Supplementary Fig. 2). The relative abundances of Ang I cleaving enzyme mRNA
(NEP, PEP, ACE) were quantified as being evenly spread.
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Figure 1. Elevated Ang-(1-7) levels in kidneys of ACE2 KO mice. (a) Kidney angiotensin concentrations of
wild-type (C57BL/6) and ACE2 knockout (ACE2 KO) mice (pg/g gram net weight). n = 8 mice per group. Data
presented as mean ± s.d. Two-tailed Student’s t-test. *P <  0.05 **P <  0.01 ***P < 0.001 vs. wild-type. (b) Relative
mRNA abundance (to beta actin) of renin in murine renal medulla (dark grey) and cortex (light grey) of wildtype and ACE2 KO. n = 8 mice per group. Data presented as mean ± s.d. One-way analysis of variance (ANOVA).
*P < 0.05 vs. medulla. (c) Renal renin activity of wild-type (black) ACE2 KO (white) assayed by Ang I formation
determination in homogenates following recombinant murine angiotensinogen spiking. n = 4 mice per group.
Data presented as mean ± s.d. Two-tailed Student’s t-test. not significant (NS) vs. wild-type.

Angiotensin Ratio

Wild-type

ACE2 KO

Ang-(1-7)/Ang I (x100)

14.3 ±  10.5

11.0 ±  5.7

Ang-(1-7)/Ang II (x100)

8.4 ±  4.3

12.6 ±  4.9

Table 1. Ratios of renal angiotensin metabolites (pg/g) in wild-type and ACE2 knockout (ACE2 KO) mice.
Data are mean ±  s.e.m. of n =  8.

Ang II independent renal Ang-(1-7) formation via NEP in mice. Due to the equal expression and
activity of the alternative Ang II to Ang-(1-7) forming enzyme PCP in wild-type and ACE2 KO, we decided to
investigate Ang-(1-7) formation via alternative pathways to explain the increased kidney Ang-(1-7) levels in
ACE2 KO. Other groups previously reported a direct conversion of Ang I to Ang-(1-7) by analysing isolated rat
glomeruli ex vivo34.
Therefore, Ang-(1-7) and Ang II formation from Ang I was measured in murine kidney homogenates (Fig. 2b)
in presence and absence of the ACE inhibitor lisinopril, ZPP and the NEP inhibitor DL-thiorphan. Due to the
weak ACE inhibitory activity of DL-thiorphan35, we used DL-thiorphan only in combination with lisinopril for
controlled complete ACE inhibition. As expected, wild-type and ACE2 KO mice showed high similarities in
the relative abundance of these two pathways (Fig. 2b). Ang II formation from Ang I was efficiently blocked by
lisinopril, while Ang-(1-7) formation remained unaffected (Fig. 2b). We concluded that Ang-(1-7) formation
might rather be produced directly from Ang I than through Ang II as an intermediate, as previously suggested36.
Importantly, 73.4 ± 2.1% of Ang I was converted directly to Ang-(1-7) while only 26.6 ± 2.1% were metabolized to
Ang II, which could be further processed by ACE2 or PCP. We concluded that the elevated renal Ang-(1-7) levels
in ACE2 KO resulted from the increased Ang I.
DL-thiorphan reduced Ang-(1-7) formation from Ang I by 75.2 ± 1.8% suggesting NEP to be the major source
of Ang-(1-7) formation in the murine kidney. The dual prolyl-carboxy-peptidase/prolyl-endo-peptidase inhibitor
ZPP resulted in a further significantly reduced Ang-(1-7) formation, however, to a much lower extent. Of note,
Scientific Reports | 6:33678 | DOI: 10.1038/srep33678
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Figure 2. Analysis of angiotensin metabolism in kidney homogenates of mice (a–c) and human (d–f ).
(a) Renal Ang II turnover to Ang-(1-7) of wild-type (black) and ACE2 KO mice (white) in presence and absence
of specific inhibitors. n = 4 per group. Data presented as mean ± s.d. One-way analysis of variance (ANOVA).
*P < 0.001 within wild-type group vs. solvent control. (b) Ang I turnover to Ang-(1-7) (left) and Ang II (right)
of wild-type (black) and ACE2 KO (white). n = 4 per group. Data presented as mean ± s.d. One-way analysis of
variance (ANOVA). *P < 0.001 vs. solvent control. (c) Enzymatic contribution to Ang II or Ang-(1-7) formation
in mice was calculated on the inhibitor sensitive angiotensin formation rate of fig. 2a,b. Data presented as
mean ±  s.d. (d) Human renal Ang II turnover to Ang-(1-7) in presence and absence of specific inhibitors. n =  5
per group. Data presented as mean ± s.d. One-way analysis of variance (ANOVA). *P < 0.001 vs. solvent control.
(e) Human Ang I turnover to Ang-(1-7) (left) and Ang II (right) in kidney homogenates. n = 5 per group. Data
presented as mean ± s.d. One-way analysis of variance (ANOVA). *P < 0.001 vs. solvent control. (f) Enzymatic
contribution to Ang II or Ang-(1-7) formation in human was calculated on the inhibitor sensitive angiotensin
formation rate of fig. 2d,e. Data presented as mean ±  s.d.

triple treatment inhibiting ACE (lisinopril), NEP (DL-thiorphan) and PEP (ZPP) did not abolish Ang-(1-7) from
Ang I completely, suggesting the presence of an alternative pathway possibly involving the metabolite Ang-(1-9).

Prominent role of NEP in Ang-(1-7) formation in the human kidney.

In order to assess potential
clinical implications, we extended the metabolic analyses to kidney biopsies of living human transplant donors,
observing several differences between mice and humans.
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Figure 3. MALDI-Imaging reveals DL-thiorphan-sensitive Ang-(1-7) formation in renal cortex of mice.
(a) Diminishing effect of increasing DL-thiophan concentrations (0 μM – 100 μM) on local turnover of Ang I
to Ang-(1-7) is shown by MALDI-Imaging. Brighter colors of the murine kidney section indicate pronounced
Ang-(1-7) formation in the renal cortex. (b) Increasing Ang-(1-7) signals depending on lisinopril concentration
(0 μM–10 μM). (c) Inhibitory capacity of 100 μM DL-thiorphan on Ang I to Ang-(1-7) turnover in presence
of 10 μM lisinopril (d) Intensity of Ang-(1-7) formation (Fig. 3c) was calculated and is given in bars. n =  4 per
group. Data presented as mean ± s.d. Two-tailed Student’s t-test. *P < 0.05 vs. 10 μM lisinopril. (e) Schematic
graph highlights the targeted angiotensin pathways of the used inhibitors.
First, in contrast to mice, ACE2 dominantly contributed to formation of Ang-(1-7) from Ang II in human
kidneys (88.2 ± 4.3% vs. 30.9 ± 0.3%) (Fig. 2d). Secondly, the ACE inhibitor lisinopril was not able to completely abolish Ang II formation in the human kidney. At least a part of ACE independent Ang II formation was
blocked by the chymase inhibitor chymostatin, supporting a role for chymase in Ang II formation in the human
kidney (Fig. 2e). However, the turnover from Ang I to Ang-(1-7) was reduced significantly in the presence of
DL-thiorphan in both humans and mice, confirming the species-independent prominent role of NEP in renal
Ang-(1-7) formation.
Human kidney biopsies subjected to angiotensin metabolic analysis were further analysed regarding the tissue
localization of angiotensin metabolizing enzymes by immunohistochemistry (Supplementary Fig. 4). Glomerular
epithelial cells displayed strong signals for NEP, while ACE2 expression appeared to be less abundant in these
cells. This expression pattern shows that NEP and its blood-derived substrate Ang I are in local proximity in vivo,
suggesting a role for NEP in Ang-(1-7) formation in the intact human kidney.

Ang I dependent Ang-(1-7) formation primarily in renal cortex of mice. To complement our
analysis in homogenates with more structurally intact tissue, we analysed the Ang I metabolism to Ang(1-7) in cryo-sections of whole murine kidneys by MALDI-Imaging 37. We obtained a dose-depended
DL-thiorphan-sensitive Ang-(1-7) signal in the cortex of murine kidney slices that were incubated with Ang I
as a substrate (Fig. 3a). MALDI imaging tracks NEP activity by measuring the intensity of Ang-(1-7) signals on
the surface of tissue slices that are incubated with an excess of Ang I as the natural substrate. In order to enhance
the readout signal, protease inhibitors are added to the incubation buffer, that are aimed to avoid the degradation
of Ang-(1-7) generated during the incubation. We observed a concentration dependent increase of Ang-(1-7)
in the presence of lisinopril (Fig. 3b). As the stabilization of the product of the investigated enzymatic reaction
is improving the signal in MALDI imaging, we decided to include lisinopril into MALDI assay. Beside blocking
the ACE mediated degradation of Ang-(1-7)38, the ACE inhibitor lisinopril prevents formation of Ang-(1-7) via
Ang II (Fig. 3e). The specificity of the obtained Ang-(1-7) signal for NEP was confirmed by the NEP inhibitor
DL-thiorphan, which was added on top of lisinopril (Fig. 3c,d). We observed a significant reduction of Ang-(1-7)
formation from Ang I (p = 0.045) suggesting a role of NEP in Ang-(1-7) formation in the intact murine kidney,
with an increased enzymatic density in the renal cortex.
NEP inhibition by LBQ657 (sacubitrilat) reduced renal Ang-(1-7) levels in vivo. Mice were treated
intraperitoneally with 50 mg/kg of the NEP inhibitor LBQ657 in order to investigate the impact of short term NEP
inhibition on kidney angiotensin levels in vivo. Administration of LBQ657 significantly reduced Ang-(1-7) levels
in the murine kidney by 53.1 ±  10.6% (p = 0.026) accompanied by a lowered Ang-(1-7)/Ang I ratio (p =  0.047)
(Table 2). No significant alteration of any other quantified angiotensin could be observed in the LBQ657 treated
group, although a clear trend towards reduced levels of angiotensins was present. Mean values for plasma equilibrium Ang-(1-7) levels and the Ang-(1-7)/Ang I ratio were also reduced in LBQ657 treated animals (Table 3).
However, p-values remained clearly above the significance threshold of 0.05.

Discussion

In this study, we dissected enzymatic Ang-(1-7) formation in the murine and human kidney, combining genetic
knockout and pharmacological inhibition with multiplex mass spectrometry (RAS fingerprint) and refined
MALDI-Imaging. Characterizing the RAS in ACE2 knockout mice by RAS fingerprint revealed increased levels
Scientific Reports | 6:33678 | DOI: 10.1038/srep33678
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Angiotensin (pg/g)

Vehicle

Ang-(1-7)

74 ±  14

35 ±  4*

952 ±  172

642 ±  99

Ang II

LBQ657

Ang I

399 ±  69

277 ±  31

Ang-(1-9)

249 ±  62

162 ±  10

Ang-(2-8)

211 ±  33

195 ±  28

Ang-(2-10)

147 ±  22

89 ±  16

Ang-(1-7)/Ang I (x100)

18.4 ±  0.59

13.4 ±  2.0*

Ang-(1-7)/Ang II (x100)

8.1 ±  1.1

6.1 ±  1.2

Table 2. Renal angiotensin metabolites (pg/g) and their ratios of mice treated with vehicle or LBQ657
(50 mg/kg). Data are mean ±  s.e.m. of n =  5. *P < 0.05 vs. vehicle.

Angiotensin (pg/ml)

Vehicle

Ang-(1-7)

39 ±  12

LBQ657
20 ±  7

Ang II

1396 ±  294

1423 ±  540

Ang I

1061 ±  142

970 ±  341

Ang-(1-5)

84 ±  11

73 ±  34

Ang-(2-8)

252 ±  56

269 ±  91

Ang-(3-8)

101 ±  20

114 ±  36

Ang-(1-7)/Ang I (x100)

3.5 ±  0.8

1.8 ±  0.2

Ang-(1-7)/Ang II (x100)

3.7 ±  1.5

1.5 ±  0.2

Table 3. Equilibrium plasma angiotensin metabolites (pg/ml) and their ratios of mice treated with vehicle
or LBQ657 (50 mg/kg). Data are mean ±  s.e.m. of n =  5.

of Ang I, Ang II and their metabolites in comparison to wild-type mice. This is in line with previous reports,
describing increased levels of Ang II in ACE2 KO mice39–41. We and others further detected increased renal
concentrations of Ang-(1-7) in ACE2 KO mice15, which seems to undermine the role of ACE2 in Ang-(1-7) formation in the kidney. Our findings point to the conclusion that the elevated Ang II levels in ACE2 KO animals are
more likely a result of the increased plasma renin than being a consequence of the reduced Ang II breakdown by
the lack of ACE2. Multiple mechanisms are known to be involved in the control of renin secretion including salt
and fluid homeostasis, sympathetic nervous system activity, blood pressure and hormonal status42. The mechanisms lying behind the up-regulation of renin in response to ACE2 KO still need to be investigated and might
involve ACE2 targets beyond the angiotensin system potentially interfering with renin secretion. Comparing
Ang-(1-7)/Ang II ratios between kidneys of wild-type and ACE2 KO mice (Table 1), challenges the classical concept that Ang-(1-7) is primarily generated via cleavage of Ang II by ACE213,43,44. Undoubtedly, the knockdown of
ACE2 has detrimental consequences on kidney45 and lung46 physiology and has been reported to be involved in
the development of diabetes-induced cardiovascular complications47 and inflammation48. But only few and controversial data are available connecting ACE2 KO with actual angiotensin concentrations, which might be in part
caused by technical issues in sample processing and subsequent angiotensin quantification. One could speculate
that ACE2 generates Ang-(1-7) especially in proximity to its cognate receptor in a local molecular environment,
which could explain the lack of impact on total plasma and tissue Ang-(1-7) levels. Beside Ang II conversion in
Ang-(1-7), ACE2 is involved in apelin signaling49, bradykinin metabolism and dynorphin A50 degradation, as well
as tryptophan uptake in the gut via a non-enzymatic mechanism41, which might affect physiological conditions
beyond RAS signaling.
Based on our observations in ACE2 KO mice, we decide to investigate Ang-(1-7) formation via alternative
pathways and found NEP as a major renal Ang-(1-7) forming enzyme via Ang I cleavage. We further compared
the relative metabolic rates in kidney homogenates and revealed species-specific similarities and differences. The
relative formation rate of Ang II and Ang-(1-7) after Ang I spike was similar between humans and mice. However,
the contribution of NEP in Ang-(1-7) formation was slightly increased in humans. Chymase activity was detected
in the human kidney only, which is in line with previous findings51. Interestingly, the relative contribution of
ACE2 to Ang-(1-7) formation was more prominent in human compared to murine kidneys. Investigation of local
turnover of Ang I on structurally intact kidneys using MALDI-Imaging showed a prominent local Ang-(1-7) generation in the renal cortex. Moreover, Ang II spiking experiments in separated cortex and medulla homogenates
(Supplementary Fig. 2) revealed a higher Ang-(1-7) formation rate in the renal cortex indicating a crucial role of
Ang-(1-7) in this compartment.
We are aware that the investigation of enzyme activities in tissue homogenates are not reflecting the in vivo
situation as tissue homogenization releases multiple proteolytic enzymes from intracellular compartments facilitating non-physiological proximity of substrates and enzymes. In order to abrogate the impact of potentially
interfering proteolytic enzymes on the assay readouts, specific inhibitor cocktails were designed to inhibit these
interfering proteases, while preserving the activity of the enzymes of interest, which was proven by the usage
of the recombinant enzymes and their specific inhibitors. While lisinopril and MLN-4760 are supposed being
Scientific Reports | 6:33678 | DOI: 10.1038/srep33678
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specific inhibitors for ACE and ACE2, respectively, chymostatin inhibits a broad range of enzymes, such as chymase, chymotrypsin and lysosomal cysteine proteinases (cathepsins, A, B, C, G, H, L). Importantly, the NEP
inhibitor DL-thiorphan has been reported to possess ACE inhibitory activity35. In fact, DL-thiorphan mediated
inhibition of ACE was one of the reasons why NEP activity in MALDI imaging and tissue homogenates was investigated in the presence of lisinopril, as complete blockade of ACE by lisinopril prevents DL-thiorphan mediated
effects on Ang-(1-7) stability.
Aiming to proof the in vivo relevance of our observations obtained in homogenate analysis and MALDI imaging,
we treated mice by intraperitoneal injection with the specific active NEP inhibitor LBQ657 (sacubitrilat) and measured endogenous renal angiotensin concentrations. Endogenous angiotensin levels in kidneys and plasma of i.p.
treated animals (Table 2 and Table 3) were elevated compared to untreated mice (Fig. 1, Supplementary Fig. 1a/b).
In order to achieve the required dose for in vivo treatment of mice with LBQ657, that has been previously chemically produced by alkaline hydrolysis (Supplementary Fig. 5) of AHU-377 (sacubitril), 50% DMSO had to be
used as a vehicle, which was different to the experiment in which we compared ACE2 KO and wild-type mice in
terms of angiotensin levels. We speculated that increased angiotensin levels observed in vehicle treated animals
might be explained by DMSO mediated hemodynamic changes, since previous telemetry experiments revealed a
temporary decrease in blood pressure in mice following DMSO administration (data not shown).
We further observed a general trend towards decreased renal angiotensin metabolite levels following NEP
inhibitor administration suggesting differences in kidney renin activity. Therefore, we used the Ang-(1-7)/Ang I
ratio as a surrogate measure for NEP activity in the kidney that is independent of overall RAS activity. However,
a potential interference of NEP inhibition on overall kidney RAS activity cannot be excluded and needs to be
investigated in further studies.
Importantly, we could confirm that the administration of the NEP inhibitor LBQ657 significantly reduced
Ang-(1-7) levels in the murine kidney, accompanied by a significant decrease in the Ang-(1-7)/Ang I ratio.
(Table 2). However, the reducing effect on Ang-(1-7) formation appeared to be less prominent in vivo when
compared to previous findings in tissue homogenates. Beside NEP, further enzymes seem to be significantly
involved in the generation of renal Ang-(1-7) in vivo as NEP inhibition by LBQ657 could not completely abolish
Ang-(1-7) levels. Importantly, the lack of the reduction in the Ang-(1-7)/Ang II ratio in ACE2 KO mice suggests
the existence of other alternative pathways of Ang-(1-7) formation that may compensate for the lack of ACE2.
It might be speculated that ACE2 KO results in an enzymatic rearrangement in the kidney, where NEP or PCP
could take over the role of ACE2 in Ang-(1-7) formation. If PCP might solely be able to compensate for ACE2
mediated Ang-(1-7) formation needs to be investigated in further studies on ACE2 knockout animals treated
with NEP inhibitors.
LC-MS/MS based analysis of equilibrium angiotensin levels in plasma was employed to characterize the soluble RAS in murine samples. Equilibrium angiotensin levels make use of the fact that angiotensinogen is present in
plasma at high concentrations, providing a stable rate of Ang I formation over a certain ex vivo incubation period,
which is also the basis for the determination of plasma renin activity (PRA). In contrast to PRA assays, where Ang
I is stabilized by using appropriate protease inhibitors, in equilibrium analysis Ang I is immediately converted to
further downstream angiotensin metabolites and equilibrium levels are established. These levels are characterized by equal formation and degradation rates of individual angiotensin metabolites in the plasma sample that
are determined by all enzymes, which are involved in plasma angiotensin metabolism. This principle is valid for
all resulting angiotensin metabolite equilibrium levels and their ratios to be a valid surrogate of RAS enzyme
activities in a plasma sample. Equilibrium angiotensin levels are generally higher compared to levels obtained
from samples collected using an appropriate protease inhibitor cocktail for immediate inhibition of angiotensinases during sampling (Supplementary Fig. 1), which has also been observed in previous studies in humans
and rats27,38. Interestingly, equilibrium angiotensin levels show a high correlation with immediately stabilized
angiotensin levels. One could speculate that the increased equilibrium levels might be caused by the absence of
endothelial receptors and enzymes during the ex vivo incubation step, therefore suggesting equilibrium angiotensin levels represent a portion of angiotensins that is visible to endothelial surfaces.
Although the trends on reduced Ang-(1-7) levels under NEP inhibition in plasma equilibrium analysis were
similar compared to angiotensin levels in kidneys, the effects did not reach significance. A possible explanation
for the more prominent effect in the kidney could be the difference in NEP abundance, since NEP is a membraneand blood cell bound enzyme, highly expressed in the kidney while hardly detectable in plasma52. As NEP has
been reported being expressed on leucocytes further investigations using whole blood are required to highlight
NEP influence on systemic renin-angiotensin-system.
However, in the context of RAS-interfering therapies, our findings indicate major biochemical and physiological differences between human and murine kidneys. The formation of the key effector molecules of the classical
and the alternative RAS (Ang II and Ang-(1-7), respectively), was significantly different between humans and
mice. The role of ACE2 in human kidney function might be underestimated by the investigation of murine model
systems, where ACE2 seems to be less involved in Ang II metabolism compared to humans. We conclude that
species-specific molecular differences within the RAS exist between mice and humans that could affect kidney
physiology and should be considered for future translational therapeutic approaches.
Our findings could be of clinical relevance for patients treated with an ACE inhibitor. ACE inhibitor treatment results in an increase of Ang I by inhibiting its conversion to Ang II27,53 and shows significant benefits in
CKD1,4,5. The increased availability of Ang I as a substrate for NEP in the kidney may have a significant impact on
Ang-(1-7) formation in vivo. While Ang I levels are elevated and Ang II as a substrate for ACE2 or PCP mediated
formation of Ang-(1-7) is less available27, NEP is likely to take over a major role in Ang-(1-7) formation. In this
context, the combined inhibition of ACE and NEP, despite showing remarkable effects on blood pressure54, might
be detrimental in therapeutic settings, where Ang-(1-7) mediates renoprotective effects9. The presence of chymase in human kidneys suggests a bypass of the inhibitory effect of ACE inhibitors on Ang II levels in humans,
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which might gain importance in pathologic conditions like CKD, where cellular re-organization of the kidney
structure occurs. Of note, it cannot be excluded that direct formation of Ang II from angiotensinogen via cathepsin G or tonin might also play a role in the maintenance of kidney Ang II levels in vivo. Nevertheless, ACE2 may
antagonize this additional pathway of Ang II formation and may serve as efficient protection from excess Ang II
in the human setting.
Our findings describe a role of NEP in the formation of the alternative, reno-protective Ang-(1-7)/MAS receptor axis in the kidney. This molecular mechanism may potentially affect the therapeutic administration of NEP
inhibitor in combination with Ang II receptor blocker, LCZ696, which was recently approved for treatment of
heart failure. The recent heart failure trial PARADIGM-HF involving over 8,000 patients had to be halted, since
LCZ696 dramatically reduced overall mortality compared to treatment with valsartan19. Beyond Ang II blockade,
the underlying mechanisms of these profound effects of LCZ696 are attributed to the stabilization of bradykinin
and natriuretic peptides by NEP inhibition. However, data from the PARAMOUNT trial further revealed an
increase in urinary albumin to creatinine ratio (UACR) in the LCZ696 treated group in patients with moderately
impaired kidney function21 indicting an involvement of NEP in kidney physiology, which could either be contributed by the direct effects of natriuretic peptides or to changes in local angiotensin metabolism.
Taking our findings together with results from clinical trials, the therapeutic inhibition of NEP in heart failure
patients, especially those suffering from renal co-morbidities, may require further investigation.

Materials and Methods
Mice Study.

All animal procedures were approved by the federal state government of middle Frankonia
(#TS-05/10, #54-2532.1-12/11, AZ 84-02.04.2012.A250) in accordance to the German animal protection law and
were performed by skilled experimenters.

Murine Kidney and Plasma Preparation (wild-type vs. ACE2 KO).

12 weeks old female wild-type
and ACE2 KO mice with C57BL/6j background were maintained at the animal care facility of the University
Erlangen-Nuremberg, Germany under a 12 h light/dark cycle, normal chow (SNIFF, Soest) and tap water
ad libitum. For dissection of kidneys, mice were deeply anaesthetized, then CO2 asphyxiated and transcardially
perfused with PBS. Harvested kidneys were immediately snap-frozen in liquid nitrogen and stored at −80 °C
until shipment for analysis. Obtained heparin plasma samples were either equilibrated for 30 min at 37 °C before
stabilization for equilibrium analysis or directly stabilized using a preformulated peptidase inhibitor cocktail
(Attoquant Diagnostics GmbH) for circulating angiotensin analysis38. Stabilized samples were snap-frozen and
stored at −80 °C until further processing.

AHU-377 (sacubitril) – LBQ657 (sacubitrilat).

The NEP inhibitor AHU-377 (sacubitril) is a prodrug
and physiologically activated in the liver by CES155. For intraperitoneal administration of the active drug LBQ657
(sacubitrilat), we chemically activated the prodrug by standard ester hydrolysis. 7-fold molar excess of NaOH
was added to AHU-377 (Sigma-Aldrich) and incubated for 6 h at 60 °C. Solution was neutralized by equimolar
hydrochlorid acid and evaporated to dryness. Chemical yield was controlled by mass spectrometry, operated in
ES-negative mode (Supplementary Fig. 5).

Murine Kidney and Plasma Preparation (Inhibitor Treatment).

10 to 12 weeks old female wild-type
with C57BL/6j background were maintained at the animal care facility of the University Duesseldorf, Germany
under a 12 h light/dark cycle, normal chew (SNIFF, Soest) and tap water ad libitum. Vehicle (50% DMSO) or
NEP-inhibitor (LBQ657 (Sigma-Aldrich): 50 mg/kg) were administrated i.p. 4 hours prior to kidney and heparin
plasma sampling. Kidneys were obtained as given above, while heparin plasma was incubated for 30 min at 37 °C
for equilibrium analysis, stabilized38 and stored at −80 °C until shipment.

Human Kidney Biopsy Preparation. This study was approved by the Ethics Committee of the Medical
University of Vienna (EK #1496/2014) and was performed in accordance to the good clinical practice guidelines.
Written informed consent was obtained before biopsies were taken perioperative from 5 kidney donors in 2014.
Renal biopsies were either snap frozen in liquid nitrogen for angiotensin metabolism analysis or fixed in formalin
for histological examination.
Immunoreactive staining. Formalin-fixed paraffin-embedded myocardial biopsies were cut to 4 μm sections, deparaffinized in xylene and rehydrated in graded ethanol and water. Antigens were unmasked by autoclaving (30 min) in retrieval buffer (Chymase, NEP: Tris/EDTA buffer pH8; ACE, ACE2, PEP, PCP: Na-citrate
buffer pH6) and endogenous peroxidase was blocked (3% H2O2). Following blockade of non-specific background
(Ultra V Block, Thermo Scientific, MA), slides were incubated in primary antibody (ACE 1:50, PEP 1:500, PCP
1:300, all Sigma-Aldrich; chymase 1:500, abcam; NEP, 1:50, Novocastra; ACE2, 1:100, R&D Systems) diluted in
1% bovine serum albumin (BSA) in PBS for 1 hour. Subsequently, slides were washed in PBS, treated with primary
antibody enhancer, HRP polymer and developed using 3,3′-diaminobenzidine enhanced by cobalt/nickelchloride (all Thermo Scientific) to form a brown/black precipitate. After counterstaining with haematoxylin (Merck,
Germany), slides were dehydrated, coverslipped and photomicrographed.
Analysis of Angiotensin Metabolism.

Metabolic RAS analysis was performed by Attoquant Diagnostics
GmbH, Vienna, Austria. Renal biopsies of mice and humans were extracted and homogenized in
phosphate-buffered saline (PBS) using low-energy sonication. The metabolism of spiked Ang I, Ang II (Fisher
Scientific) or recombinant murine AGT (Sino Biological Inc.) for the renin activity assay, respectively, was assayed
in homogenates after ex vivo incubation at 37 °C in presence or absence of specific enzyme inhibitors. Lisinopril
(10 μM, Sigma-Aldrich), chymostatin (10 μM, Sigma-Aldrich), Z-Pro-Prolinal (20 μM, Sigma-Aldrich),
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MLN-4760 (10 μM, Merck-Millipore), DL-thiorphan (100 μM, Sigma-Aldrich). Aminopeptidase Inhibitor
(10 μM, Sigma-Aldrich) was added to all samples.
The enzyme activity was calculated by determining the inhibitor sensitive part of product formation in incubated samples and is presented as a product formation in ng of the corresponding angiotensin product per μg
protein per hour. In order to proof linearity of the assay in dependence of enzyme abundance, Ang I and Ang
II metabolism were assayed in serial diluted kidney homogenates (Supplementary Fig. 6). All experiments were
performed in the linear range of the assay.

Angiotensin Peptide Quantification.

Angiotensin peptide quantification by liquid chromatography
tandem-mass spectrometry analysis (LC-MS/MS) was performed by Attoquant Diagnostics GmbH (Vienna,
Austria) as previously described27,31.

MALDI-Imaging. Consecutive tissue sections were prepared from fresh frozen kidneys (n = 4) as previously described37 and incubated with 772 μM Ang I at 37 °C for 5 min. Inhibition of renal Ang-(1–7) formation was tested using reaction mixtures spiked with lisinopril (10 μM, Sigma-Aldrich) alone or in combination
with the neprilysin-inhibitor DL-thiorphan (100 μM, Sigma-Aldrich) or Aminopeptidase-A inhibitor (10 μM,
Sigma-Aldrich) was present in all samples. The imaging technique is described in detail elsewhere37.
Real Time PCR. Relative abundance of ACE, ACE2, PEP, PCP, renin and NEP mRNAs in murine renal
medulla and cortex were analysed by semiquantitative real time PCR. Kidneys were separated into medulla
and cortex and further mechanically disrupted in TriFast (PeqLab, Erlangen, Germany) using a glass douncer.
Total RNA was extracted using the PeqGold RNA isolation kit (PeqLab) and 1 μg of RNA reversely transcribed
using QuantiTect transcriptases (QIAGEN) and random polyT primers. Resulting cDNA was diluted (1:30)
in DNase/RNase free water (Gibco) and directly used in amplification reactions. Predeveloped TaqMan probe/
primer pair assays (Supplementary Fig. 4b) and accessory reagents (PCR SuperMix-UDG, ROX reference dye, all
from Life Technologies) were used for amplification. PCR reactions were performed at a 10 μl scale on an Applied
Biosystems SDS 7900 real time PCR System (Life Technologies) in quadruplicates; relative quantification was performed by the ΔΔC
 T method (Schmittgen and Livak 2008), normalizing target gene expression on Actb/β-Actin.

®

®

Statistic. Unpaired Student’s t-test was used to evaluate the differences between two groups. For more than
two groups, ordinary one-way ANOVA followed by Bonferroni’s multiple comparison correction was used.
For real-time PCR, relative quantification values were tested for normal distribution using the D’Agostino &
Pearson omnibus normality test and afterwards analysed by one-way ANOVA with Tukey’s test.
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